ID   TIA1_HUMAN              Reviewed;         386 AA.
AC   P31483; Q53SS9; Q96B58;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 3.
DT   18-JUN-2025, entry version 219.
DE   RecName: Full=Cytotoxic granule associated RNA binding protein TIA1 {ECO:0000312|HGNC:HGNC:11802};
DE   AltName: Full=Nucleolysin TIA-1 isoform p40 {ECO:0000305};
DE   AltName: Full=RNA-binding protein TIA-1;
DE   AltName: Full=T-cell-restricted intracellular antigen-1;
DE            Short=TIA-1;
DE   AltName: Full=p40-TIA-1;
GN   Name=TIA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND FUNCTION.
RX   PubMed=1934064; DOI=10.1016/0092-8674(91)90536-8;
RA   Tian Q., Streuli M., Saito H., Schlossman S.F., Anderson P.;
RT   "A polyadenylate binding protein localized to the granules of cytolytic
RT   lymphocytes induces DNA fragmentation in target cells.";
RL   Cell 67:629-639(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Leukocyte;
RX   PubMed=8176212;
RA   Kawakami A., Tian Q., Streuli M., Poe M., Edelhoff S., Disteche C.M.,
RA   Anderson P.;
RT   "Intron-exon organization and chromosomal localization of the human TIA-1
RT   gene.";
RL   J. Immunol. 152:4937-4945(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH FASTK, AND PHOSPHORYLATION.
RX   PubMed=7544399; DOI=10.1084/jem.182.3.865;
RA   Tian Q., Taupin J.-L., Elledge S., Robertson M., Anderson P.;
RT   "Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during
RT   Fas-mediated apoptosis.";
RL   J. Exp. Med. 182:865-874(1995).
RN   [7]
RP   FUNCTION, DOMAIN, AND RNA BINDING.
RX   PubMed=8576255; DOI=10.1074/jbc.271.5.2783;
RA   Dember L.M., Kim N.D., Liu K.Q., Anderson P.;
RT   "Individual RNA recognition motifs of TIA-1 and TIAR have different RNA
RT   binding specificities.";
RL   J. Biol. Chem. 271:2783-2788(1996).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=10613902; DOI=10.1083/jcb.147.7.1431;
RA   Kedersha N.L., Gupta M., Li W., Miller I., Anderson P.;
RT   "RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2
RT   alpha to the assembly of mammalian stress granules.";
RL   J. Cell Biol. 147:1431-1442(1999).
RN   [9]
RP   FUNCTION.
RX   PubMed=11106748; DOI=10.1016/s1097-2765(00)00107-6;
RA   Foerch P., Puig O., Kedersha N., Martinez C., Granneman S., Seraphin B.,
RA   Anderson P., Valcarcel J.;
RT   "The apoptosis-promoting factor TIA-1 is a regulator of alternative pre-
RT   mRNA splicing.";
RL   Mol. Cell 6:1089-1098(2000).
RN   [10]
RP   FUNCTION, INTERACTION WITH SNRPC, DOMAIN, AND RNA BINDING.
RX   PubMed=12486009; DOI=10.1093/emboj/cdf668;
RA   Foerch P., Puig O., Martinez C., Seraphin B., Valcarcel J.;
RT   "The splicing regulator TIA-1 interacts with U1-C to promote U1 snRNP
RT   recruitment to 5' splice sites.";
RL   EMBO J. 21:6882-6892(2002).
RN   [11]
RP   FUNCTION.
RX   PubMed=14966131; DOI=10.1074/jbc.m313439200;
RA   Zuccato E., Buratti E., Stuani C., Baralle F.E., Pagani F.;
RT   "An intronic polypyrimidine-rich element downstream of the donor site
RT   modulates cystic fibrosis transmembrane conductance regulator exon 9
RT   alternative splicing.";
RL   J. Biol. Chem. 279:16980-16988(2004).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15371533; DOI=10.1091/mbc.e04-08-0715;
RA   Gilks N., Kedersha N., Ayodele M., Shen L., Stoecklin G., Dember L.M.,
RA   Anderson P.;
RT   "Stress granule assembly is mediated by prion-like aggregation of TIA-1.";
RL   Mol. Biol. Cell 15:5383-5398(2004).
RN   [13]
RP   INTERACTION WITH FASTK.
RX   PubMed=17135269; DOI=10.1074/jbc.c600198200;
RA   Izquierdo J.M., Valcarcel J.;
RT   "Fas-activated serine/threonine kinase (FAST K) synergizes with TIA-1/TIAR
RT   proteins to regulate Fas alternative splicing.";
RL   J. Biol. Chem. 282:1539-1543(2007).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17488725; DOI=10.1074/jbc.m700688200;
RA   Izquierdo J.M., Valcarcel J.;
RT   "Two isoforms of the T-cell intracellular antigen 1 (TIA-1) splicing factor
RT   display distinct splicing regulation activities. Control of TIA-1 isoform
RT   ratio by TIA-1-related protein.";
RL   J. Biol. Chem. 282:19410-19417(2007).
RN   [15]
RP   FUNCTION.
RX   PubMed=17580305; DOI=10.1074/jbc.m702717200;
RA   McAlinden A., Liang L., Mukudai Y., Imamura T., Sandell L.J.;
RT   "Nuclear protein TIA-1 regulates COL2A1 alternative splicing and interacts
RT   with precursor mRNA and genomic DNA.";
RL   J. Biol. Chem. 282:24444-24454(2007).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17984221; DOI=10.1128/mcb.01226-07;
RA   Kim J.E., Ryu I., Kim W.J., Song O.K., Ryu J., Kwon M.Y., Kim J.H.,
RA   Jang S.K.;
RT   "Proline-rich transcript in brain protein induces stress granule
RT   formation.";
RL   Mol. Cell. Biol. 28:803-813(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 105-186, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18201561; DOI=10.1016/j.bbrc.2008.01.027;
RA   Kumar A.O., Swenson M.C., Benning M.M., Kielkopf C.L.;
RT   "Structure of the central RNA recognition motif of human TIA-1 at 1.95A
RT   resolution.";
RL   Biochem. Biophys. Res. Commun. 367:813-819(2008).
RN   [20]
RP   VARIANT WDM LYS-384, AND CHARACTERIZATION OF VARIANT WDM LYS-384.
RX   PubMed=23401021; DOI=10.1002/ana.23831;
RA   Hackman P., Sarparanta J., Lehtinen S., Vihola A., Evila A., Jonson P.H.,
RA   Luque H., Kere J., Screen M., Chinnery P.F., Ahlberg G., Edstrom L.,
RA   Udd B.;
RT   "Welander distal myopathy is caused by a mutation in the RNA-binding
RT   protein TIA1.";
RL   Ann. Neurol. 73:500-509(2013).
RN   [21]
RP   VARIANT WDM LYS-384.
RX   PubMed=23348830; DOI=10.1002/humu.22282;
RA   Klar J., Sobol M., Melberg A., Maebert K., Ameur A., Johansson A.C.,
RA   Feuk L., Entesarian M., Orlen H., Casar-Borota O., Dahl N.;
RT   "Welander distal myopathy caused by an ancient founder mutation in TIA1
RT   associated with perturbed splicing.";
RL   Hum. Mutat. 34:572-577(2013).
RN   [22]
RP   INVOLVEMENT IN ALS26, VARIANTS ALS26 MET-294; ILE-334; ARG-355; MET-360;
RP   LEU-362 AND THR-381, AND CHARACTERIZATION OF VARIANTS ALS26 LEU-362 AND WDM
RP   LYS-384.
RX   PubMed=28817800; DOI=10.1016/j.neuron.2017.07.025;
RA   Mackenzie I.R., Nicholson A.M., Sarkar M., Messing J., Purice M.D.,
RA   Pottier C., Annu K., Baker M., Perkerson R.B., Kurti A., Matchett B.J.,
RA   Mittag T., Temirov J., Hsiung G.R., Krieger C., Murray M.E., Kato M.,
RA   Fryer J.D., Petrucelli L., Zinman L., Weintraub S., Mesulam M., Keith J.,
RA   Zivkovic S.A., Hirsch-Reinshagen V., Roos R.P., Zuechner S.,
RA   Graff-Radford N.R., Petersen R.C., Caselli R.J., Wszolek Z.K., Finger E.,
RA   Lippa C., Lacomis D., Stewart H., Dickson D.W., Kim H.J., Rogaeva E.,
RA   Bigio E., Boylan K.B., Taylor J.P., Rademakers R.;
RT   "TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal
RT   Dementia Promote Phase Separation and Alter Stress Granule Dynamics.";
RL   Neuron 95:808-816.e9(2017).
CC   -!- FUNCTION: RNA-binding protein involved in the regulation of alternative
CC       pre-RNA splicing and mRNA translation by binding to uridine-rich (U-
CC       rich) RNA sequences (PubMed:11106748, PubMed:12486009, PubMed:17488725,
CC       PubMed:8576255). Binds to U-rich sequences immediately downstream from
CC       a 5' splice sites in a uridine-rich small nuclear ribonucleoprotein (U
CC       snRNP)-dependent fashion, thereby modulating alternative pre-RNA
CC       splicing (PubMed:11106748, PubMed:8576255). Preferably binds to the U-
CC       rich IAS1 sequence in a U1 snRNP-dependent manner; this binding is
CC       optimal if a 5' splice site is adjacent to IAS1 (By similarity).
CC       Activates the use of heterologous 5' splice sites; the activation
CC       depends on the intron sequence downstream from the 5' splice site, with
CC       a preference for a downstream U-rich sequence (PubMed:11106748). By
CC       interacting with SNRPC/U1-C, promotes recruitment and binding of
CC       spliceosomal U1 snRNP to 5' splice sites followed by U-rich sequences,
CC       thereby facilitating atypical 5' splice site recognition by U1 snRNP
CC       (PubMed:11106748, PubMed:12486009, PubMed:17488725). Activates splicing
CC       of alternative exons with weak 5' splice sites followed by a U-rich
CC       stretch on its own pre-mRNA and on TIAR mRNA (By similarity). Acts as a
CC       modulator of alternative splicing for the apoptotic FAS receptor,
CC       thereby promoting apoptosis (PubMed:11106748, PubMed:17488725,
CC       PubMed:1934064). Binds to the 5' splice site region of FAS intron 5 to
CC       promote accumulation of transcripts that include exon 6 at the expense
CC       of transcripts in which exon 6 is skipped, thereby leading to the
CC       transcription of a membrane-bound apoptotic FAS receptor, which
CC       promotes apoptosis (PubMed:11106748, PubMed:17488725, PubMed:1934064).
CC       Binds to a conserved AU-rich cis element in COL2A1 intron 2 and
CC       modulates alternative splicing of COL2A1 exon 2 (PubMed:17580305). Also
CC       binds to the equivalent AT-rich element in COL2A1 genomic DNA, and may
CC       thereby be involved in the regulation of transcription
CC       (PubMed:17580305). Binds specifically to a polypyrimidine-rich
CC       controlling element (PCE) located between the weak 5' splice site and
CC       the intronic splicing silencer of CFTR mRNA to promote exon 9
CC       inclusion, thereby antagonizing PTB1 and its role in exon skipping of
CC       CFTR exon 9 (PubMed:14966131). Involved in the repression of mRNA
CC       translation by binding to AU-rich elements (AREs) located in mRNA 3'
CC       untranslated regions (3' UTRs), including target ARE-bearing mRNAs
CC       encoding TNF and PTGS2 (By similarity). Also participates in the
CC       cellular response to environmental stress, by acting downstream of the
CC       stress-induced phosphorylation of EIF2S1/EIF2A to promote the
CC       recruitment of untranslated mRNAs to cytoplasmic stress granules (SGs),
CC       leading to stress-induced translational arrest (PubMed:10613902).
CC       Formation and recruitment to SGs is regulated by Zn(2+) (By
CC       similarity). Possesses nucleolytic activity against cytotoxic
CC       lymphocyte target cells (PubMed:1934064).
CC       {ECO:0000250|UniProtKB:P52912, ECO:0000269|PubMed:10613902,
CC       ECO:0000269|PubMed:11106748, ECO:0000269|PubMed:12486009,
CC       ECO:0000269|PubMed:14966131, ECO:0000269|PubMed:17488725,
CC       ECO:0000269|PubMed:17580305, ECO:0000269|PubMed:1934064,
CC       ECO:0000269|PubMed:8576255}.
CC   -!- FUNCTION: [Isoform Short]: Displays enhanced splicing regulatory
CC       activity compared with TIA isoform Long. {ECO:0000269|PubMed:17488725}.
CC   -!- SUBUNIT: Homooligomer; homooligomerization is induced by Zn(2+) (By
CC       similarity). Interacts with FASTK; the interactions leads to its
CC       phosphorylation (PubMed:17135269, PubMed:7544399). Interacts (via RRM1
CC       and the C-terminal glutamine-rich (Q) sequence) with SNRPC/U1-C (via N-
CC       terminus); thereby facilitating spliceosomal U1 snRNP recruitment to 5'
CC       splice sites (PubMed:12486009). {ECO:0000250|UniProtKB:P52912,
CC       ECO:0000269|PubMed:12486009, ECO:0000269|PubMed:17135269,
CC       ECO:0000269|PubMed:7544399}.
CC   -!- INTERACTION:
CC       P31483; P08621: SNRNP70; NbExp=2; IntAct=EBI-1387216, EBI-1049228;
CC       P31483; P09012: SNRPA; NbExp=4; IntAct=EBI-1387216, EBI-607085;
CC       P31483; P09234: SNRPC; NbExp=6; IntAct=EBI-1387216, EBI-766589;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10613902,
CC       ECO:0000269|PubMed:15371533, ECO:0000269|PubMed:17984221,
CC       ECO:0000305|PubMed:18201561}. Cytoplasm {ECO:0000269|PubMed:17488725}.
CC       Cytoplasm, Stress granule {ECO:0000269|PubMed:10613902,
CC       ECO:0000269|PubMed:15371533, ECO:0000269|PubMed:17984221}.
CC       Note=Accumulates in cytoplasmic stress granules (SG) following cellular
CC       damage (PubMed:10613902, PubMed:15371533). Recruitment to SG is induced
CC       by Zn(2+) (By similarity). {ECO:0000250|UniProtKB:P52912,
CC       ECO:0000269|PubMed:10613902, ECO:0000269|PubMed:15371533}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Long; Synonyms=a {ECO:0000303|PubMed:17488725};
CC         IsoId=P31483-1; Sequence=Displayed;
CC       Name=Short; Synonyms=b {ECO:0000303|PubMed:17488725};
CC         IsoId=P31483-2; Sequence=VSP_005892;
CC       Name=3;
CC         IsoId=P31483-3; Sequence=VSP_057403, VSP_057404;
CC   -!- TISSUE SPECIFICITY: Expressed in heart, small intestine, kidney, liver,
CC       lung, skeletal muscle, testes, pancreas, and ovary (at protein level).
CC       {ECO:0000269|PubMed:17488725}.
CC   -!- DOMAIN: The RNA recognition motif domains RRM 2 and RRM 3 are necessary
CC       and sufficient for binding to uridine-rich target pre-mRNA.
CC       {ECO:0000269|PubMed:12486009, ECO:0000269|PubMed:8576255}.
CC   -!- DOMAIN: The RRM 1 and RRM 2 domains are required for the localization
CC       to stress granules (SGs) and for the recruitment of TIAR1 and poly(A)
CC       RNA to SGs in response to stress. {ECO:0000269|PubMed:10613902}.
CC   -!- DOMAIN: The RRM2 domain and the C-terminal residues 287-340 contribute
CC       to nuclear localization. {ECO:0000250|UniProtKB:P52912}.
CC   -!- DOMAIN: The RRM3 domain mediates nuclear export.
CC       {ECO:0000250|UniProtKB:P52912}.
CC   -!- DOMAIN: The C-terminal glutamine-rich (Q) sequence in combination with
CC       the RRM 1 domain is required for the interaction with SNRPC/U1-C and to
CC       facilitate recruitment of spliceosomal U1 snRNP to 5' splice sites.
CC       {ECO:0000269|PubMed:12486009}.
CC   -!- PTM: Phosphorylated by FASTK; phosphorylation occurs after FAS ligation
CC       in FAS-mediated apoptosis and before DNA fragmentation.
CC       {ECO:0000269|PubMed:7544399}.
CC   -!- DISEASE: Welander distal myopathy (WDM) [MIM:604454]: An autosomal
CC       dominant disorder characterized by adult onset of distal muscle
CC       weakness predominantly affecting the distal long extensors of the
CC       hands, with slow progression to involve all small hand muscles and the
CC       lower legs. Skeletal muscle biopsy shows myopathic changes and
CC       prominent rimmed vacuoles. Rare homozygous patients showed earlier
CC       onset, faster progression, and proximal muscle involvement.
CC       {ECO:0000269|PubMed:23348830, ECO:0000269|PubMed:23401021}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Amyotrophic lateral sclerosis 26, with or without
CC       frontotemporal dementia (ALS26) [MIM:619133]: A form of amyotrophic
CC       lateral sclerosis, a neurodegenerative disorder affecting upper motor
CC       neurons in the brain and lower motor neurons in the brain stem and
CC       spinal cord, resulting in fatal paralysis. Sensory abnormalities are
CC       absent. The pathologic hallmarks of the disease include pallor of the
CC       corticospinal tract due to loss of motor neurons, presence of
CC       ubiquitin-positive inclusions within surviving motor neurons, and
CC       deposition of pathologic aggregates. The etiology of amyotrophic
CC       lateral sclerosis is likely to be multifactorial, involving both
CC       genetic and environmental factors. The disease is inherited in 5-10% of
CC       the cases. ALS26 inheritance is autosomal dominant. Some patients may
CC       develop frontotemporal dementia. {ECO:0000269|PubMed:28817800}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M77142; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S70114; AAD14053.1; -; Genomic_DNA.
DR   EMBL; AC016700; AAX93193.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAW99824.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAW99826.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAW99827.1; -; Genomic_DNA.
DR   EMBL; BC015944; AAH15944.1; -; mRNA.
DR   CCDS; CCDS1900.1; -. [P31483-2]
DR   CCDS; CCDS1901.1; -. [P31483-1]
DR   CCDS; CCDS86846.1; -. [P31483-3]
DR   PIR; A39293; A39293.
DR   RefSeq; NP_001338447.1; NM_001351518.2. [P31483-3]
DR   RefSeq; NP_071320.2; NM_022037.4. [P31483-2]
DR   RefSeq; NP_071505.2; NM_022173.4. [P31483-1]
DR   PDB; 2MJN; NMR; -; A=105-285.
DR   PDB; 3BS9; X-ray; 1.95 A; A/B=105-186.
DR   PDB; 5ITH; X-ray; 2.31 A; A=105-194.
DR   PDB; 5O2V; NMR; -; A=1-92.
DR   PDB; 5O3J; X-ray; 2.97 A; A=104-181.
DR   PDB; 6ELD; X-ray; 2.48 A; A=1-92.
DR   PDB; 7VI4; EM; 0.95 A; A=377-386.
DR   PDB; 7VI5; EM; 1.76 A; A=377-386.
DR   PDBsum; 2MJN; -.
DR   PDBsum; 3BS9; -.
DR   PDBsum; 5ITH; -.
DR   PDBsum; 5O2V; -.
DR   PDBsum; 5O3J; -.
DR   PDBsum; 6ELD; -.
DR   PDBsum; 7VI4; -.
DR   PDBsum; 7VI5; -.
DR   AlphaFoldDB; P31483; -.
DR   SASBDB; P31483; -.
DR   SMR; P31483; -.
DR   BioGRID; 112928; 113.
DR   FunCoup; P31483; 4023.
DR   IntAct; P31483; 59.
DR   MINT; P31483; -.
DR   STRING; 9606.ENSP00000401371; -.
DR   GlyGen; P31483; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P31483; -.
DR   MetOSite; P31483; -.
DR   PhosphoSitePlus; P31483; -.
DR   SwissPalm; P31483; -.
DR   BioMuta; TIA1; -.
DR   DMDM; 206729905; -.
DR   CPTAC; CPTAC-1645; -.
DR   jPOST; P31483; -.
DR   MassIVE; P31483; -.
DR   PaxDb; 9606-ENSP00000401371; -.
DR   PeptideAtlas; P31483; -.
DR   ProteomicsDB; 54790; -. [P31483-1]
DR   ProteomicsDB; 54791; -. [P31483-2]
DR   ProteomicsDB; 76048; -.
DR   Pumba; P31483; -.
DR   Antibodypedia; 16302; 603 antibodies from 42 providers.
DR   DNASU; 7072; -.
DR   YCharOS; P31483; Tested 12 antibodies from 7 manufacturers.
DR   Ensembl; ENST00000415783.6; ENSP00000404023.2; ENSG00000116001.17. [P31483-2]
DR   Ensembl; ENST00000416149.6; ENSP00000413751.2; ENSG00000116001.17. [P31483-3]
DR   Ensembl; ENST00000433529.7; ENSP00000401371.2; ENSG00000116001.17. [P31483-1]
DR   GeneID; 7072; -.
DR   KEGG; hsa:7072; -.
DR   MANE-Select; ENST00000433529.7; ENSP00000401371.2; NM_022173.4; NP_071505.2.
DR   UCSC; uc002sgj.5; human. [P31483-1]
DR   UCSC; uc002sgm.4; human.
DR   AGR; HGNC:11802; -.
DR   CTD; 7072; -.
DR   DisGeNET; 7072; -.
DR   GeneCards; TIA1; -.
DR   HGNC; HGNC:11802; TIA1.
DR   HPA; ENSG00000116001; Low tissue specificity.
DR   MalaCards; TIA1; -.
DR   MIM; 603518; gene.
DR   MIM; 604454; phenotype.
DR   MIM; 619133; phenotype.
DR   OpenTargets; ENSG00000116001; -.
DR   Orphanet; 603; Distal myopathy, Welander type.
DR   VEuPathDB; HostDB:ENSG00000116001; -.
DR   eggNOG; KOG0148; Eukaryota.
DR   GeneTree; ENSGT00940000154962; -.
DR   HOGENOM; CLU_012062_15_6_1; -.
DR   InParanoid; P31483; -.
DR   OMA; VRIFKMQ; -.
DR   OrthoDB; 439808at2759; -.
DR   PAN-GO; P31483; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; P31483; -.
DR   PathwayCommons; P31483; -.
DR   Reactome; R-HSA-6803529; FGFR2 alternative splicing.
DR   SignaLink; P31483; -.
DR   BioGRID-ORCS; 7072; 21 hits in 1155 CRISPR screens.
DR   CD-CODE; 0A6B6B10; Synthetic Condensate 000350.
DR   CD-CODE; 1249081A; Synthetic Condensate 000025.
DR   CD-CODE; 1855AB2E; Synthetic Condensate 000027.
DR   CD-CODE; 232F8A39; P-body.
DR   CD-CODE; 6209F224; Synthetic Condensate 000281.
DR   CD-CODE; 67BDA0FF; Synthetic Condensate 000032.
DR   CD-CODE; 9B5E283A; Synthetic Condensate 000373.
DR   CD-CODE; DEE660B4; Stress granule.
DR   CD-CODE; E1879998; Synthetic Condensate 000375.
DR   ChiTaRS; TIA1; human.
DR   EvolutionaryTrace; P31483; -.
DR   GenomeRNAi; 7072; -.
DR   Pharos; P31483; Tbio.
DR   PRO; PR:P31483; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P31483; protein.
DR   Bgee; ENSG00000116001; Expressed in right uterine tube and 204 other cell types or tissues.
DR   ExpressionAtlas; P31483; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0010494; C:cytoplasmic stress granule; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0097165; C:nuclear stress granule; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:Ensembl.
DR   GO; GO:0035925; F:mRNA 3'-UTR AU-rich region binding; IEA:Ensembl.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; ISS:UniProtKB.
DR   GO; GO:0008143; F:poly(A) binding; TAS:ProtInc.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0001818; P:negative regulation of cytokine production; IEA:Ensembl.
DR   GO; GO:0017148; P:negative regulation of translation; ISS:UniProtKB.
DR   GO; GO:1904037; P:positive regulation of epithelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:1903608; P:protein localization to cytoplasmic stress granule; IMP:AgBase.
DR   GO; GO:0000381; P:regulation of alternative mRNA splicing, via spliceosome; IDA:UniProtKB.
DR   GO; GO:0048024; P:regulation of mRNA splicing, via spliceosome; IDA:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR   GO; GO:0034063; P:stress granule assembly; IDA:UniProtKB.
DR   CDD; cd12615; RRM1_TIA1; 1.
DR   CDD; cd12618; RRM2_TIA1; 1.
DR   CDD; cd12620; RRM3_TIAR; 1.
DR   FunFam; 3.30.70.330:FF:000951; nucleolysin TIA-1 isoform X7; 1.
DR   FunFam; 3.30.70.330:FF:000038; Nucleolysin tiar isoform 1; 1.
DR   FunFam; 3.30.70.330:FF:000045; Nucleolysin tiar isoform 1; 1.
DR   Gene3D; 3.30.70.330; -; 3.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR003954; RRM_dom_euk.
DR   InterPro; IPR034827; TIA-1_RRM1.
DR   InterPro; IPR034830; TIA1_RRM2.
DR   InterPro; IPR034496; TIAR_RRM3.
DR   PANTHER; PTHR10352; EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT G; 1.
DR   Pfam; PF00076; RRM_1; 3.
DR   SMART; SM00360; RRM; 3.
DR   SMART; SM00361; RRM_1; 3.
DR   SUPFAM; SSF54928; RNA-binding domain, RBD; 3.
DR   PROSITE; PS50102; RRM; 3.
DR   neXtProt; NX_P31483; -.
DR   PharmGKB; PA36511; -.
DR   TreeFam; TF312915; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Amyotrophic lateral sclerosis; Apoptosis; Cytoplasm; Disease variant;
KW   mRNA processing; mRNA splicing; Neurodegeneration; Nucleus;
KW   Proteomics identification; Reference proteome; Repeat; RNA-binding.
FT   CHAIN           1..386
FT                   /note="Cytotoxic granule associated RNA binding protein
FT                   TIA1"
FT                   /id="PRO_0000031031"
FT   DOMAIN          7..83
FT                   /note="RRM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          106..184
FT                   /note="RRM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          214..286
FT                   /note="RRM 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   REGION          354..386
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        363..376
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   VAR_SEQ         93..104
FT                   /note="SSTVVSTQRSQD -> N (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:1934064"
FT                   /id="VSP_005892"
FT   VAR_SEQ         195..214
FT                   /note="SNTKQLSYDEVVNQSSPSNC -> CRCIGEEKEMWNFGEKYARF (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_057403"
FT   VAR_SEQ         215..386
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_057404"
FT   VARIANT         294
FT                   /note="V -> M (in ALS26; uncertain significance;
FT                   dbSNP:rs144296151)"
FT                   /evidence="ECO:0000269|PubMed:28817800"
FT                   /id="VAR_085357"
FT   VARIANT         334
FT                   /note="M -> I (in ALS26; uncertain significance;
FT                   dbSNP:rs747006488)"
FT                   /evidence="ECO:0000269|PubMed:28817800"
FT                   /id="VAR_085358"
FT   VARIANT         355
FT                   /note="G -> R (in ALS26; uncertain significance;
FT                   dbSNP:rs372889101)"
FT                   /evidence="ECO:0000269|PubMed:28817800"
FT                   /id="VAR_085359"
FT   VARIANT         360
FT                   /note="V -> M (in ALS26; uncertain significance;
FT                   dbSNP:rs201905164)"
FT                   /evidence="ECO:0000269|PubMed:28817800"
FT                   /id="VAR_085360"
FT   VARIANT         362
FT                   /note="P -> L (in ALS26; accelerated formation of TIA1
FT                   amyloid-like fibrils; impaired stress granule disassembly;
FT                   accumulation of insoluble TARDBP/TDP43-positive stress
FT                   granules; dbSNP:rs757332023)"
FT                   /evidence="ECO:0000269|PubMed:28817800"
FT                   /id="VAR_085361"
FT   VARIANT         381
FT                   /note="A -> T (in ALS26; uncertain significance;
FT                   dbSNP:rs768554955)"
FT                   /evidence="ECO:0000269|PubMed:28817800"
FT                   /id="VAR_085362"
FT   VARIANT         384
FT                   /note="E -> K (in WDM; results in a mild increase of stress
FT                   granule numbers compared to controls; impaired stress
FT                   granule disassembly; dbSNP:rs747068278)"
FT                   /evidence="ECO:0000269|PubMed:23348830,
FT                   ECO:0000269|PubMed:23401021, ECO:0000269|PubMed:28817800"
FT                   /id="VAR_069897"
FT   CONFLICT        116
FT                   /note="E -> Q (in Ref. 1; M77142)"
FT                   /evidence="ECO:0000305"
FT   HELIX           2..4
FT                   /evidence="ECO:0007829|PDB:5O2V"
FT   STRAND          8..13
FT                   /evidence="ECO:0007829|PDB:6ELD"
FT   HELIX           20..28
FT                   /evidence="ECO:0007829|PDB:6ELD"
FT   STRAND          33..39
FT                   /evidence="ECO:0007829|PDB:6ELD"
FT   STRAND          42..44
FT                   /evidence="ECO:0007829|PDB:5O2V"
FT   STRAND          48..55
FT                   /evidence="ECO:0007829|PDB:6ELD"
FT   HELIX           56..66
FT                   /evidence="ECO:0007829|PDB:6ELD"
FT   STRAND          70..75
FT                   /evidence="ECO:0007829|PDB:6ELD"
FT   STRAND          77..82
FT                   /evidence="ECO:0007829|PDB:6ELD"
FT   STRAND          106..112
FT                   /evidence="ECO:0007829|PDB:3BS9"
FT   HELIX           119..126
FT                   /evidence="ECO:0007829|PDB:3BS9"
FT   HELIX           127..129
FT                   /evidence="ECO:0007829|PDB:3BS9"
FT   STRAND          132..139
FT                   /evidence="ECO:0007829|PDB:3BS9"
FT   TURN            141..143
FT                   /evidence="ECO:0007829|PDB:3BS9"
FT   STRAND          146..156
FT                   /evidence="ECO:0007829|PDB:3BS9"
FT   HELIX           157..167
FT                   /evidence="ECO:0007829|PDB:3BS9"
FT   STRAND          171..176
FT                   /evidence="ECO:0007829|PDB:5O3J"
FT   STRAND          178..182
FT                   /evidence="ECO:0007829|PDB:3BS9"
FT   HELIX           202..206
FT                   /evidence="ECO:0007829|PDB:2MJN"
FT   STRAND          215..219
FT                   /evidence="ECO:0007829|PDB:2MJN"
FT   HELIX           227..234
FT                   /evidence="ECO:0007829|PDB:2MJN"
FT   TURN            235..237
FT                   /evidence="ECO:0007829|PDB:2MJN"
FT   STRAND          240..246
FT                   /evidence="ECO:0007829|PDB:2MJN"
FT   TURN            247..250
FT                   /evidence="ECO:0007829|PDB:2MJN"
FT   STRAND          251..258
FT                   /evidence="ECO:0007829|PDB:2MJN"
FT   HELIX           259..269
FT                   /evidence="ECO:0007829|PDB:2MJN"
FT   STRAND          280..283
FT                   /evidence="ECO:0007829|PDB:2MJN"
SQ   SEQUENCE   386 AA;  42963 MW;  4FD2E8B7AF57A0D6 CRC64;
     MEDEMPKTLY VGNLSRDVTE ALILQLFSQI GPCKNCKMIM DTAGNDPYCF VEFHEHRHAA
     AALAAMNGRK IMGKEVKVNW ATTPSSQKKD TSSSTVVSTQ RSQDHFHVFV GDLSPEITTE
     DIKAAFAPFG RISDARVVKD MATGKSKGYG FVSFFNKWDA ENAIQQMGGQ WLGGRQIRTN
     WATRKPPAPK STYESNTKQL SYDEVVNQSS PSNCTVYCGG VTSGLTEQLM RQTFSPFGQI
     MEIRVFPDKG YSFVRFNSHE SAAHAIVSVN GTTIEGHVVK CYWGKETLDM INPVQQQNQI
     GYPQPYGQWG QWYGNAQQIG QYMPNGWQVP AYGMYGQAWN QQGFNQTQSS APWMGPNYGV
     QPPQGQNGSM LPNQPSGYRV AGYETQ
//
